View Older Stories View More Recent Stories

Apr 13, 2022 05:26PM Genmab (GMAB) and AbbVie (ABBV) Announce Topline Results for Epcoritamab From Phase 1/2 Trial in Patients with R/R LBCL
Apr 13, 2022 05:26PM Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Apr 13, 2022 05:25PM Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Apr 13, 2022 05:25PM Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Apr 8, 2022 05:56AM Genmab A/S (GMAB) Announces Initial Resolution of Arbitration with Janssen Relating to Daratumumab License Agreement
Apr 7, 2022 07:44PM Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement
Apr 7, 2022 07:44PM Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement
Mar 29, 2022 02:34PM Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Mar 8, 2022 07:32AM Genmab (GMAB) and Abbvie (ABBV) Granted FDA Orphan-Drug Designation to Epcoritamab
Mar 8, 2022 07:30AM Genmab Announces U.S. Food and Drug Administration Granted Orphan-Drug Designation to Epcoritamab (DuoBody®-CD3xCD20) in Follicular Lymphoma
Mar 1, 2022 09:14AM Genmab Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer
Feb 25, 2022 04:19PM Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Feb 24, 2022 10:01AM Genmab A/S (GMAB) and Seagen (SGEN) Report Data on Tisotumab Vedotin in Patients with Head and Neck Squamous Cell Carcinoma
Feb 24, 2022 10:00AM Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
Feb 24, 2022 10:00AM Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
Feb 24, 2022 10:00AM Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
Feb 24, 2022 06:01AM Notice to Convene the Annual General Meeting of Genmab A/S
Feb 16, 2022 02:14PM Genmab Files Annual Report with the U.S. Securities and Exchange Commission
Feb 16, 2022 11:00AM Genmab Publishes 2021 Annual Report
Jan 26, 2022 08:44AM Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Jan 25, 2022 06:33AM Genmab A/S (GMAB) Reports 2021 Net Sales of DARZALEX of $6.02B
Jan 25, 2022 06:30AM Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021
Jan 4, 2022 09:00AM Genmab A/S (GMAB) and Synaffix Enter into License Agreement for ADC Technology
Jan 4, 2022 09:00AM Genmab and Synaffix Enter into License Agreement for ADC Technology
Jan 4, 2022 09:00AM Genmab and Synaffix Enter into License Agreement for ADC Technology
Jan 4, 2022 09:00AM Genmab and Synaffix Enter into License Agreement for ADC Technology
Nov 22, 2021 03:59PM Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Nov 4, 2021 04:24PM Genmab Improves its 2021 Financial Guidance
Nov 4, 2021 09:06AM Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)
Nov 4, 2021 09:05AM Genmab Announces Multiple Abstracts to be Presented at the 63rd Annual Meeting and Exposition of the American Society of Hematology (ASH)
Oct 19, 2021 06:37AM Genmab (GMAB) Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
Oct 19, 2021 06:29AM Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
Oct 1, 2021 08:00AM Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
Oct 1, 2021 08:00AM Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
Sep 21, 2021 02:22PM Capital Increase in Genmab as a Result of Employee Warrant Exercise
Sep 20, 2021 05:03PM Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
Sep 20, 2021 05:01PM Seagen (SGEN), Genmab Announce FDA Accelerated Approval for TIVDAK in Previously Treated Recurrent or Metastatic Cervical Cancer
Sep 20, 2021 05:00PM Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
Sep 20, 2021 05:00PM Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
Sep 20, 2021 05:00PM Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
Sep 20, 2021 05:39AM Seagen (SGEN) and Genmab (GMAB) Present Encouraging Results From Two Cohorts of Phase 1b/2 innovaTV 205 Trial
Sep 19, 2021 11:30AM Genmab and Seagen Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
Sep 19, 2021 11:30AM Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
Sep 9, 2021 07:00AM Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell non-Hodgkin’s Lymphoma (B-NHL) Published in The Lancet
Sep 9, 2021 07:00AM Clinical Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) Published in The Lancet
Apr 9, 2021 04:00PM Genmab A/S (GMAB) and Seagen (SGEN) Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin BLA for Patients with Recurrent or Metastatic Cervical Cancer
Apr 9, 2021 04:00PM Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
Apr 9, 2021 04:00PM  Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
Apr 9, 2021 04:00PM Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
Apr 9, 2021 04:00PM Seagen and Genmab Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
View More Recent Stories View Older Stories